Oakworth Capital’s United Therapeutics UTHR Stock Holding History

Oakworth Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$602K	Hold	1,111	–	–	0.03%	134
2026 Q1	$659K	Hold	1,111	–	–	0.03%	122
2025 Q4	$541K	Hold	1,111	–	–	0.03%	130
2025 Q3	$466K	Hold	1,111	–	–	0.03%	137
2025 Q2	$319K	Hold	1,111	–	–	0.02%	161
2025 Q1	$342K	Hold	1,111	–	–	0.02%	153
2024 Q4	$392K	Hold	1,111	–	–	0.03%	145
2024 Q3	$398K	Hold	1,111	–	–	0.03%	142
2024 Q2	$354K	Hold	1,111	–	–	0.03%	141
2024 Q1	$255K	Hold	1,111	–	–	0.02%	173
2023 Q4	$244K	Hold	1,111	–	–	0.02%	169
2023 Q3	$251K	Hold	1,111	–	–	0.02%	147
2023 Q2	$245K	Hold	1,111	–	–	0.02%	152
2023 Q1	$249K	Hold	1,111	–	–	0.02%	147
2022 Q4	$309K	Hold	1,111	–	–	0.03%	124
2022 Q3	$233K	Hold	1,111	–	–	0.03%	144
2022 Q2	$262K	Buy	+1,111	New	+$226K	0.03%	143
2018 Q1	–	Sell	-64	Closed	-$8K	–	649
2017 Q4	$8K	Sell	64 -445	-87%	-$56.6K	﹤0.01%	479
2017 Q3	$67K	Sell	509 -224	-31%	-$28.6K	0.02%	263
2017 Q2	$95K	Sell	733 -123	-14%	-$15.3K	0.03%	224
2017 Q1	$116K	Hold	856	–	–	0.03%	204
2016 Q4	$107K	Hold	856	–	–	0.04%	204
2016 Q3	$102K	Sell	856 -287	-25%	-$34.5K	0.04%	193
2016 Q2	$136K	Hold	1,143	–	–	0.05%	176
2016 Q1	$128K	Buy	+1,143	New	+$145K	0.05%	156

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Oakworth Capital's UTHR Position: Q2 2026 in Review

Oakworth Capital held its United Therapeutics (UTHR) position steady in Q2 2026 at 1,111 shares worth $602K. The position accounts for 0.03% of the portfolio, ranked #134.

Oakworth Capital first reported a position in UTHR in Q1 2016 and has held it in 25 quarters since. The position peaked at $659K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Oakworth Capital held 1,111 shares of United Therapeutics worth $602K as of Q2 2026.
Oakworth Capital left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up 0.03% of Oakworth Capital's portfolio in Q2 2026, its #134 holding.
Oakworth Capital first reported a position in United Therapeutics in Q1 2016 and has held it in 25 quarters since.
Oakworth Capital's United Therapeutics position peaked at $659K in Q1 2026.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Oakworth Capital's 13F filing for Q2 2026, filed 22 Jul 2026.